116 related articles for article (PubMed ID: 23973115)
1. Attributable costs of differentiated thyroid cancer in the elderly Medicare population.
Boltz MM; Hollenbeak CS; Schaefer E; Goldenberg D; Saunders BD
Surgery; 2013 Dec; 154(6):1363-9; discussion 1369-70. PubMed ID: 23973115
[TBL] [Abstract][Full Text] [Related]
2. Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.
Hollenbeak CS; Nikkel LE; Schaefer EW; Alemao E; Ghahramani N; Raman JD
J Manag Care Pharm; 2011 Oct; 17(8):610-20. PubMed ID: 21942302
[TBL] [Abstract][Full Text] [Related]
3. Optimal Cutoff Age for Predicting Mortality Associated with Differentiated Thyroid Cancer.
Kim SJ; Myong JP; Suh H; Lee KE; Youn YK
PLoS One; 2015; 10(6):e0130848. PubMed ID: 26102084
[TBL] [Abstract][Full Text] [Related]
4. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients.
Oyer SL; Fritsch VA; Lentsch EJ
Ann Otol Rhinol Laryngol; 2014 Feb; 123(2):94-100. PubMed ID: 24574464
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tumor Size on Risk of Metastatic Disease and Survival for Thyroid Cancer: Implications for Biopsy Guidelines.
Nguyen XV; Roy Choudhury K; Tessler FN; Hoang JK
Thyroid; 2018 Mar; 28(3):295-300. PubMed ID: 29373949
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of papillary thyroid cancer surveillance.
Wang LY; Roman BR; Migliacci JC; Palmer FL; Tuttle RM; Shaha AR; Shah JP; Patel SG; Ganly I
Cancer; 2015 Dec; 121(23):4132-40. PubMed ID: 26280253
[TBL] [Abstract][Full Text] [Related]
7. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.
Bhattacharyya N
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):115-23. PubMed ID: 12574769
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the costs of active surveillance and immediate surgery in the management of low-risk papillary microcarcinoma of the thyroid.
Oda H; Miyauchi A; Ito Y; Sasai H; Masuoka H; Yabuta T; Fukushima M; Higashiyama T; Kihara M; Kobayashi K; Miya A
Endocr J; 2017 Jan; 64(1):59-64. PubMed ID: 27667647
[TBL] [Abstract][Full Text] [Related]
9. Initial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: A health care service provider perspective.
Lang BH; Wong CK; Chan CT
Eur J Surg Oncol; 2015 Jun; 41(6):758-65. PubMed ID: 25680952
[TBL] [Abstract][Full Text] [Related]
10. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
11. Follicular variant papillary thyroid carcinoma in a pediatric population.
Lerner J; Goldfarb M
Pediatr Blood Cancer; 2015 Nov; 62(11):1942-6. PubMed ID: 26131690
[TBL] [Abstract][Full Text] [Related]
12. [Recovery rate in differentiated thyroid cancer. Experiences of one of the Hungarian clinical centers].
Szujó S; Bajnok L; Bódis B; Nemes O; Rucz K; Mezősi E
Orv Hetil; 2018 Jun; 159(22):878-884. PubMed ID: 29806478
[TBL] [Abstract][Full Text] [Related]
13. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma.
Zaydfudim V; Feurer ID; Griffin MR; Phay JE
Surgery; 2008 Dec; 144(6):1070-7; discussion 1077-8. PubMed ID: 19041020
[TBL] [Abstract][Full Text] [Related]
14. Impact of surgical resection extension on outcome for primary well-differentiated thyroid cancer-a retrospective analysis.
Muller S; Senne M; Kirschniak A; Königsrainer A; Bares R; Falch C
World J Surg Oncol; 2017 Oct; 15(1):190. PubMed ID: 29065879
[TBL] [Abstract][Full Text] [Related]
15. Annual financial impact of well-differentiated thyroid cancer care in the United States.
Lubitz CC; Kong CY; McMahon PM; Daniels GH; Chen Y; Economopoulos KP; Gazelle GS; Weinstein MC
Cancer; 2014 May; 120(9):1345-52. PubMed ID: 24481684
[TBL] [Abstract][Full Text] [Related]
16. Determinants of Medicare Costs for Elderly Patients With Oral Cavity and Pharyngeal Cancers.
Hollenbeak CS; Kulaylat AN; Mackley H; Koch W; Schaefer EW; Goldenberg D
JAMA Otolaryngol Head Neck Surg; 2015 Jul; 141(7):628-35. PubMed ID: 26042925
[TBL] [Abstract][Full Text] [Related]
17. [Clinical picture of differentiated thyroid carcinoma in the T1 stage].
Czarniecka A; Włoch J; Lange D
Wiad Lek; 2001; 54 Suppl 1():225-33. PubMed ID: 12182030
[TBL] [Abstract][Full Text] [Related]
18. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
19. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
20. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
